Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | UBE2I | P63279 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236440 | 0.88 | SLC2A1 (0.54) | NCF1USP2MAPTKDM4EALDH1A1 | |
| SCHEMBL6105362 | 0.86 | NCF1 (0.56) | NCF1USP2MAPTKDM4EALDH1A1 | |
| SCHEMBL6231576 | 0.85 | NCF1 (0.46) | NCF1USP2P2RX7MAPTKDM4E | |
| SCHEMBL31620790 | 0.79 | NPSR1 (0.61) | NCF1USP2P2RX7MAPTKDM4E | |
| SCHEMBL23925278 | 0.78 | ALDH1A1 (0.51) | USP2P2RX7MAPTKDM4EALDH1A1 | |
| SCHEMBL6100736 | 0.74 | EPHB4 (0.57) | P2RX7MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL4733419 | 0.72 | NCF1 (0.74) | NCF1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL581984 | 0.72 | HPGD (0.53) | P2RX7MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL18433843 | 0.70 | KDM1A (0.52) | MAPTKDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL4733334 | 0.70 | NCF1 (1.00) | NCF1MAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153865-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1430030-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| EP-1430030-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003018561-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | NCF1 511/4885USP2 3952/4885P2RX7 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.